Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction

Author:

Raghu Ganesh,Nathan Steven D.,Behr Juergen,Brown Kevin K.,Egan James J.,Kawut Steven M.,Flaherty Kevin R.,Martinez Fernando J.,Wells Athol U.,Shao Lixin,Zhou Huafeng,Henig Noreen,Szwarcberg Javier,Gillies Hunter,Montgomery Alan B.,O'Riordan Thomas G.

Abstract

The clinical course of pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) is not known except in advanced disease.488 subjects in a placebo-controlled study of ambrisentan in IPF with mild–moderate restriction in lung volume, underwent right heart catheterisation (RHC) at baseline and 117 subjects (24%) had repeated haemodynamic measurements at 48 weeks.The subjects were categorised into a) World Health Organization (WHO) Group 3 PH (PH associated with pulmonary disease), n=68 (14%); b) WHO Group 2 PH (PH associated with left-sided cardiac disease), n=25 (5%); c) no PH but elevated pulmonary artery wedge pressure (PAWP), n=21 (4%); and d) no PH but without elevation of PAWP, n=374 (77%). The WHO Group 3 PH subjects had a lower diffusion capacity, 6MWD and oxygen saturation compared to the subjects with no PH. There was no significant change in mean pulmonary arterial pressure with ambrisenten or placebo after 12 months.Subjects with IPF associated with WHO Group 3 PH had impaired gas exchange and exercise capacity compared to patients without PH. An additional 9% of the subjects had haemodynamic evidence of subclinical left-ventricular dysfunction. Pulmonary artery pressures remained stable over 1 year in the majority of the cohort.

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Cited by 120 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Functional Roles of CD26/DPP4 in Bleomycin-Induced Pulmonary Hypertension Associated with Interstitial Lung Disease;International Journal of Molecular Sciences;2024-01-06

2. Tyvaso DPI: Drug-device characteristics and patient clinical considerations;Pulmonary Pharmacology & Therapeutics;2023-12

3. What changed after the 2022 guidelines for pulmonary hypertension?;European Journal of Internal Medicine;2023-12

4. Tubulointerstitielle Nephritis und Hantavirus-Infektion;DMW - Deutsche Medizinische Wochenschrift;2023-11

5. Pulmonale Hypertonie bei Lungenerkrankungen und/oder Hypoxie;DMW - Deutsche Medizinische Wochenschrift;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3